RO4938581, a GABAA-Α5 Negative Allosteric Modulator Rescued Behavioral and EEG Phenotypes of a Mouse Model of Dup15q Syndrome

Why It Matters

It identifies a druggable mechanism underlying Dup15q neurodevelopmental deficits and offers a translational path for α5‑selective modulators, addressing a major unmet need for disease‑modifying treatments.

Key Takeaways

• GABA A‑α5 receptors overexpressed ~1.5‑fold in Dup15q mice
• RO4938581 reduced beta‑band EEG power and improved reversal learning
• Social interaction deficits normalized after chronic RO4938581 treatment
• Enhanced inhibitory transmission linked to α5 receptor overactivity
• Findings support α5 NAMs as potential Dup15q therapeutics

Pulse Analysis

Dup15q syndrome results from duplications of the 15q11‑q13 region, producing a constellation of neurodevelopmental impairments such as intellectual disability, autism spectrum features, and refractory seizures. The duplicated segment contains several GABR genes (GABRA5, GABRB3, GABRG3) that encode α5‑containing GABA A receptors, which are known to mediate tonic inhibition in limbic circuits. Clinical observations of heightened beta‑band activity on EEG and atypical responses to benzodiazepines have long suggested that excess GABA A‑α5 signaling contributes to the disorder’s pathophysiology. Targeting this specific receptor subtype therefore represents a rational, mechanism‑based therapeutic strategy.

In the present preclinical investigation, 15q duplication mice displayed a 1.5‑fold increase in GABA A‑α5 receptor density across cortex, hippocampus and striatum, accompanied by elevated spontaneous inhibitory postsynaptic currents and amplified paired‑pulse inhibition in CA1 pyramidal cells. These neurophysiological changes translated into a pronounced beta‑band EEG elevation, mirroring the human biomarker. Chronic oral dosing of RO4938581, a highly selective negative allosteric modulator of α5 receptors, lowered beta power by roughly 9 % and restored normal paired‑pulse ratios. Behaviorally, treated mice showed normalized social interaction and faster reversal learning in the Morris water maze, indicating improved cognitive flexibility.

The data provide compelling proof‑of‑concept that selective α5 NAMs can modulate both electrophysiological and behavioral hallmarks of Dup15q syndrome, positioning this approach as a viable candidate for disease‑modifying therapy. Although a previous clinical trial of the α5 NAM basmisanil failed to meet efficacy endpoints, the current mechanistic insights suggest that dosing, treatment duration, or patient stratification may need refinement. Ongoing efforts should explore broader brain region effects, long‑term safety, and potential synergism with seizure‑control regimens. Successful translation could alleviate the substantial caregiver burden and open new avenues for treating other neurodevelopmental disorders linked to GABAergic dysregulation.